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Abstract
Objective This study aims to evaluate the clinical characteristics of patients with postoperative ulcerative colitis developing
extremely early-onset pouchitis within 4 weeks of restoration of gastrointestinal continuity.
Material and Methods This retrospective study involved 225 consecutive patients from January 2000 to May 2011 who
underwent ileal pouch–anal anastomosis for ulcerative colitis with a minimum follow-up of 12 months. Extremely early-
onset pouchitis was defined as pouchitis developing within 4 weeks of restoration of gastrointestinal continuity. Patients with
pouchitis were divided into extremely early-onset pouchitis and non-extremely early-onset pouchitis groups for comparison.
Results Of 212 patients who met the inclusion criteria, 62 had pouchitis (29.2 %). Eight (3.8 %) patients developed extremely
early-onset pouchitis. There was a significant difference in the dosage of steroid per month just before colectomy between the
two groups (P00.039). The modified Pouchitis Disease Activity Index score for patients with extremely early-onset pouchitis
was higher than in patients with non-extremely early-onset pouchitis (P00.0009). The occurrence of extremely early-onset
pouchitis was associated with the development of chronic pouchitis (P00.0056).
Conclusion Extremely early-onset pouchitis may be related to high steroid dosages before colectomy and may be more
severe than pouchitis that occurs >4 weeks after restoration of gastrointestinal continuity.
Keywords Ulcerative colitis . Corticosteroids . Pouchitis
Introduction
Pouchitis, a nonspecific inflammatory condition of the ileal
pouch reservoir, is the most common long-term complication
in patients who have undergone ileal pouch–anal anastomosis
(IPAA), and it significantly affects patients’ quality of life.1
The reported cumulative risk of developing pouchitis
varies widely, ranging from 15 to 50 % in patients with
ulcerative colitis (UC), and may be even higher2–5. It occurs
most commonly within the first 6 months after IPAA and
develops in 7–15 % of patients.2,4,6–8
Patients with pouchitis have a wide range of clinical
presentations.9 To the best of our knowledge, the relation-
ship between onset days and clinical characteristics of pou-
chitis has not been fully examined in previous studies. We
analyzed the histories of patients with UC who developed
pouchitis within 4 weeks of ileostomy closure. Identification
of the clinical characteristics of patients with extremely
early-onset pouchitis (EEOP) is important for recognition
of early postoperative complications and assurance of effec-
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All 225 consecutive patients from January 2000 to May
2011, who underwent IPAA for UC with a minimum
follow-up of 12 months in our unit, were enrolled. Patients
were reviewed at 3-month intervals for the first postopera-
tive year and every 6 months or as needed, thereafter.
Standard Operation
The standard operation was a mucosal restorative proc-
tocolectomy with hand-sewn IPAA using an 18 cm two-
limbed J-shaped ileal pouch. Of the 225 patients, 223
patients underwent hand-sewn IPAA, with two patients
with anal sphincter dysfunction undergoing stapled
IPAA. Closure of the ileostomy was performed approx-
imately 3 months after IPAA if an intact pouch without
anastomotic leakage was confirmed just before ileos-
tomy closure. We routinely examined ileal pouch–anal
anastomosis using digital examination, manometry, and
defecography before ileostomy closure. Our surgeons
performed bougienage just before ileostomy closure for
the patients with anastomotic stricture, and/or patients
repeated self-bougienage after ileostomy closure.
Diagnosis of Pouchitis
All patients with pouchitis were diagnosed using a combi-
nation of clinical and endoscopic techniques. Biopsies were
not routinely taken. Pouchitis was defined as a modified
Pouchitis Disease Activity Index (PDAI) score of ≥5
points.10 We performed endoscopy for all of the patients
with suspected pouchitis. Endoscopic findings included ede-
ma, granularity, friability, loss of vascular pattern, mucoid
exudate, and ulceration, but excluded staple-line ulcer. We
performed digital examination of the ileal pouch–anal anas-
tomosis before pouchoscopy. Secondary pouchitis (e.g.,
anastomotic stricture, pelvic sepsis, pouch ischemia, Clos-
tridium difficile infection, cytomegalovirus infection and
regular use of nonsteroidal anti-inflammatory drugs), and
Crohn’s disease were actively excluded before diagnosing
pouchitis. The onset days of pouchitis were defined as the
time period from restoration of gastrointestinal continuity to
endoscopic diagnosis at the first episode. EEOP was defined
as pouchitis that developed within 4 weeks of restoration of
gastrointestinal continuity. Non-EEOP was defined as pou-
chitis that developed >4 weeks after restoration of gastroin-
testinal continuity. Absence of pouchitis was defined as a
modified PDAI score of ≤4 points. Pouchitis was classified
as acute and chronic pouchitis.11 Acute pouchitis was de-
fined as <4-week duration of symptoms and chronic pou-
chitis as >4-week duration. Antibiotic-responsive pouchitis
was defined as an episode of pouchitis that responded to a 2-
week course of antibiotics. Antibiotic-dependent pouchitis
was defined as disease requiring long-term, continuous
antibiotic therapy to maintain remission. Antibiotic–refrac-
tory pouchitis fails to respond to antibiotics and typically
requires oral or topical 5-aminosalicylates, corticosteroid
therapy, or oral immunomodulator therapy.11 Antibiotic-
dependent and antibiotic-refractory phenotypes were cate-
gorized as chronic pouchitis. We divided patients with pou-
chitis into EEOP and non-EEOP groups according to onset
days, for comparison.
Possible factors related to the development of EEOP
included: gender (male), age at initial surgery, >32 years;
disease duration of <6 years; type of disease (acute fulmi-
nating vs. relapsing–remitting vs. chronic continuous); ex-
tent of colitis (left-sided colitis); severity of colitis (severe);
extraintestinal manifestation; total dosage of steroid before
colectomy of >8 g; dosage of steroid per month just before
surgery >600 mg; use of immunomodulators; emergency or
urgent operation at first operation; operation stages (two vs.
three stages); and pelvic sepsis. These factors were assessed
using univariate and multivariate logistic regression analy-
ses to determine the significant factors related to EEOP
among patients with pouchitis. We justified age at initial
surgery of 32 years; disease duration of 6 years; total dosage
of steroid before surgery of 8 g; and dosage of steroid per
month just before surgery of 600 mg as cutoff values using
receiver–operator characteristic curves.
Statistical Analysis
Quantitative data were expressed as mean±SD (range). Sta-
tistical analysis was performed using the chi-square test or
Fisher’s exact test and the Mann–Whitney U test for quan-
titative and qualitative variables using JMP version 5 (SAS
Institute, Inc., Cary, NC, USA). All variables associated
with EEOP with P<0.4 in univariate analysis of categorical
data were examined consecutively using multivariate anal-
ysis logistic regression. A P value of <0.05 was considered
significant.
Results
Of the 225 patients, 13 with an ileostomy or who had
undergone ileostomy reconstruction for pelvic sepsis or
perianal fistula were excluded. Of the 212 patients who
met the inclusion criteria, 62 had pouchitis (29.2 %). Neither
of the two patients who underwent stapled IPAA developed
cuffitis or pouchitis. All of the patients with pelvic sepsis
and perianal fistula were radiographically confirmed to be
improved before ileostomy closure. No patients with pou-
chitis had concurrent anastomotic stricture when they devel-
oped pouchitis. Eight (3.8 %) patients developed EEOP. The
median number of days between restoration of gastrointes-
tinal continuity and first pouchitis onset was 587.5 days
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(range, 6–3,352 days). Table 1 shows the characteristics of
patients with EEOP. Six male and two female patients with a
mean age of 38±13 years (19–58 years) developed EEOP.
Seven of eight patients had total colitis, and four of eight
had severe colitis. The average cumulative dosage of steroid
administered before colectomy in the patients with EEOP
was 17.6 g. The average dosage of steroid per month just
before colectomy in patients with EEOP was 734 mg.
Of the eight patients who developed EEOP, two had
pelvic sepsis, two had perianal fistula, two had small bowel
obstruction, and one had portal vein thrombi after IPAA. All
of the pelvic sepsis and small bowel obstruction patients
improved before ileostomy closure. Two patients developed
perianal fistula 3 and 5 months after ileostomy closure,
respectively, and seton drainage improved the perianal fis-
tulas. One patient with portal vein thrombi required warfarin
therapy. None of the patients with EEOP had concurrent
postoperative complications when they developed pouchitis
except the patient with portal vein thrombi.
The clinical characteristics of the non-EEOP and EEOP
patients are shown in Table 2. Univariate analysis revealed a
significant difference in the dosage of steroid per month just
before colectomy between the two groups (P00.025). Therewas
no difference in gender, age at initial surgery, disease duration,
type of disease, extent of colitis, severity of colitis, extraintestinal
manifestation, cumulative dosage of steroid before colectomy,
use of immunomodulators, emergency or urgent operation at
first operation, operation stages, or pelvic sepsis between patients
Table 2 The clinical characteristics of the non-EEOP and EEOP patients
Factors Non-EEOP EEOP P
n054 n08
Gender (male/female) 30/24 6/2 0.45
Age at initial surgery (years) 32±15 38±13 0.24
Disease duration (years) 7.5±6.9 5.5±6.2 0.28
Type of disease (acute fulminating/relapse–remitting/chronic continuous) 5/38/11 1/4/3 0.49
Extent of colitis (left-sided colitis/total colitis) 7/47 2/6 0.33
Severity of colitis (severe/moderate/mild) 11/32/11 2/5/1 0.86
Extraintestinal manifestation (Y/N) 2/52 0/8 1.00
Total dosage of steroid before surgery (g) 19.1±19.6 17.6±13.8 0.90
Dosage of steroid per month just before surgery (mg) 518±450 734±146 0.03
Immunomodulator (Y/N) 22/32 4/4 0.71
Emergency or urgent operation at first operation (Y/N) 11/43 1/7 0.59
Operation stages (one stage/two stage/three stage) 3/37/14 0/7/1 0.52
Postoperative pelvic abscess (Y/N) 8/46 2/6 0.60
EEOP extremely early-onset pounchitis, non-EEOP pouchitis excluding extremely early-onset pouchitis
Table 3 The results of univari-
ate analysis of categorical data Factors Odds ratio 95%CI P
Gender (male) 1.35 0.85–2.15 0.45
Age at initial surgery (>32 years) 4.04 0.75–21.89 0.13
Disease duration (<6 years) 1.79 0.39–8.27 0.45
Type of disease (chronic continuous) 2.35 0.48–11.35 0.36
Type of disease (relapse–remitting) 0.42 0.09–1.89 0.42
Type of disease (acute fulminating) 1.40 0.14–13.8 0.58
Extent of colitis (left-sided colitis) 2.24 0.37–13.36 0.33
Severity of colitis (severe) 1.30 0.23–7.36 0.67
Total dosage of steroid before surgery (>8 g) 1.08 0.24–4.76 1.00
Dosage of steroid per month just before surgery (>600 mg) 4.12 0.88–19.82 0.10
Use of immunomodulator (Y) 1.45 0.33–6.44 0.71
Emergency or urgent operation at first operation (Y) 0.56 0.06–5.00 1.00
Operation stages (two stage) 3.22 0.37–28.24 0.42
Operation stages (three stage) 0.41 0.05–3.57 0.67
Postoperative pelvic abscess (Y) 1.22 0.13–11.27 1.00
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with non-EEOP and EEOP. The results of univariate analysis of
categorical data did not reveal a significant difference between
the two groups (Table 3). Multivariate analysis was performed
using four factors: age at initial surgery >32 years, type of disease
(chronic continuous), extent of colitis (left-sided colitis), or dos-
age of steroid per month just before surgery >600 mg. Multivar-
iate analysis showed that the dosage of steroid per month just
before surgery was significantly associated with EEOP (P0
0.039; Table 4).
Comparisons of severity between patients with non-
EEOP and EEOP are shown in Table 5. The median number
of days between restoration of gastrointestinal continuity
and first pouchitis onset was 737 days in patients with
non-EEOP and 11 days in patients with EEOP. The modified
PDAI score (including clinical criteria and endoscopic cri-
teria) at first onset in patients with EEOP was higher than in
patients with non-EEOP (P00.0009). The occurrence of
EEOP was significantly associated with the development
of chronic pouchitis at first onset compared with non-
EEOP patients (P00.0056). None of the patients with pou-
chitis required permanent ileostomy for refractory pouchitis.
Discussion
Abdelrazeq et al.12 reported that the first episode of pouchi-
tis occurred within 6 months of restoration of gastrointesti-
nal continuity in 45 % of patients who developed pouchitis.
The mean interval from the beginning of pouch function to
the occurrence of the first episode of pouchitis was 5 months
(range, 0.5–48 months). Other previous reports indicated
that the incidence of the first attack of pouchitis was highest
during the first 6 months after restoration of gastrointestinal
continuity, that the mean interval from the beginning
of pouch function to the first episode of pouchitis was
5–17 months, and that the range of onset was 2 days to
156 months.5,6,13–15 However, to the best of our knowledge,
no previous studies of EEOP have fully examined the rela-
tionship between onset days and clinical characteristics of
pouchitis.
Several studies have reported an increased incidence of
pouchitis in patients with extraintestinal manifestations, pri-
mary sclerosing cholangitis, and genetic factors (IL-1ra,
NOD2/CARD 15, and TNF genes).2,4–6,11,13,16–18 Recent
studies have reported a relationship between the occurrence
of pouchitis and preoperative steroid use.13,19,20 Fleshner et
al.13 reported that clinical factors associated with the develop-
ment of acute pouchitis include the use of a steroid before
colectomy, although they did not describe the use or dose of
the steroid in detail. Kalkan et al.19 reported that a high
preoperative Disease Activity Index score and steroid depen-
dency are independent risk factors for the development of
pouchitis. They suggested that more severe disease activity
in the preoperative period may pose an increased risk for the
development of pouchitis. Nakamura et al.20 reported that
many joint symptoms could be the result of alterations in the
steroid dose taken by patients prior to surgery and that the
presence of joint symptoms during steroid tapering is a sig-
nificant risk factor for the development of pouchitis. In our
study, there was a significant difference in the dosage of
steroid per month just before colectomy between patients with
EEOP and with non-EEOP. The mechanism of how steroid
use relates to EEOP remains unclear. Although patients with
more aggressive disease may have a higher incidence of
pouchitis after surgery, this trend was not seen in patients
taking other, more potent immunosuppressive agents, before
IPAA.13 Suzuki et al.21 reported a relationship between the
modified PDAI score at the first diagnosis of pouchitis and the
subsequent clinical course. Patients with chronic, frequent,
and antibiotic-dependent or refractory pouchitis had higher
Table 4 Multivariate analysis
showing the dosage of
steroid per month just before
surgery
Odds ratio 95%CI P
Age at initial surgery (>32 years) 3.60 0.66–25.55 0.14
Type of disease (chronic continuous) 4.69 0.63–44.83 0.13
Extent of colitis (left-sided colitis) 1.58 0.08–6.05 0.67
Dosage of steroid per month just before surgery (>600 mg) 6.26 1.09–52.78 0.039
Table 5 Comparisons of sever-





pouchitis, PDAI Pouchitis Dis-
ease Activity Index
Factors Non-EEOP (n054) EEOP P
Modified PDAI 6.1±1.5 8.8±2.0 0.0009
Clinical criteria 2.9±0.8 4.0±0.9 0.0031
Endoscopic criteria 3.2±1.0 4.8±1.4 0.0035
Classification categories for pouchitis
subtypes (acute/chronic)
42/12 2/6 0.0056
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modified PDAI scores than did patients with acute, infrequent,
and antibiotic-responsive pouchitis. However, they did not
describe the relationship between onset days and modified
PDAI score. In this study, patients with EEOP were
associated with higher modified PDAI score and the
development of chronic pouchitis compared with non-
EEOP patients. There is a possibility that patients with
EEOP could be diagnosed earlier because more severe
symptomatic pouchitis is easier to detect.
The limits of the present study relate to the small numb-
ers in the two groups. Hoda et al.22 showed that patients
with postoperative complications, specifically anastomotic
complications, were more likely to develop chronic pouchi-
tis. Because of the small sample size, this study may not
have shown differences in pelvic sepsis between non-EEOP
and EEOP, which was significantly related to chronic pou-
chitis. In addition, diagnosing pouchitis without biopsy may
lead to diagnostic bias. New criteria for the diagnosis of
pouchitis were proposed in Japan. These criteria are based
on clinical symptoms and endoscopic findings that are
clearly categorized in the atlas and exclude infectious enter-
itis, anastomotic insufficiency, pelvic infection, anal dys-
function, and Crohn’s disease. Advantages of the new
criteria include ease of bedside diagnosis without the calcu-
lation of points required by the other criteria for pouchitis.23
We diagnosed pouchitis based on clinical symptoms and
endoscopic findings in our patients.
Conclusion
The present study is the first to report the characteristics of
EEOP occurring within 4 weeks of restoration of gastroin-
testinal continuity. The results show that EEOP has charac-
teristics that differ from those of non-EEOP. Some studies
have reported an increased incidence of pouchitis in patients
who were administered steroids. In particular, the dosage of
steroid per month just before colectomy may affect the early
occurrence of pouchitis. This study suggests that EEOP may
be related to a high preoperative dosage of steroid and may
be more severe than pouchitis that occurs >4 weeks after
restoration of gastrointestinal continuity. Recognition of the
clinical characteristics of EEOP may ensure effective man-
agement for patients with UC in the early postoperative
period. Regardless of the reasons why an increased inci-
dence of pouchitis was observed in patients who were
administered steroids, further studies on this observation
may provide valuable insights into the pathogenesis of
pouchitis.
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